<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4571">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04728347</url>
  </required_header>
  <id_info>
    <org_study_id>ARCT-021-02</org_study_id>
    <nct_id>NCT04728347</nct_id>
  </id_info>
  <brief_title>Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021</brief_title>
  <official_title>A Phase 2a, Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcturus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcturus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study enrolling healthy adults that participated in Study ARCT-021-01&#xD;
      (the Parent Study). Participants will receive either a single injection of ARCT-021 or no&#xD;
      injection and be followed for up to 365 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2a, open-label study enrolling up to 106 healthy adults that participated in&#xD;
      Study ARCT-021-01 (the Parent Study). Participants will enter this study approximately 3&#xD;
      months after their final study visit in the Parent Study. Participants that received placebo&#xD;
      in the Parent Study or who are seronegative for SARS-CoV-2 neutralizing antibodies at&#xD;
      screening will receive a single dose of ARCT-021 and will be followed for 365 days.&#xD;
      Participants that received two injections of ARCT-021 in the Parent Study will not receive&#xD;
      any further injections of ARCT-021 and will be followed for 281 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of participants reporting solicited local adverse events</measure>
    <time_frame>for 7 days following last study vaccine dose administration</time_frame>
    <description>Adverse events reported daily in a diary that reflect common symptoms or findings at the injection site following vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of participants reporting solicited systemic adverse events</measure>
    <time_frame>for 7 days following last study vaccine dose administration</time_frame>
    <description>Adverse events reported daily in a diary that reflect generalized symptoms following vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of participants reporting adverse events</measure>
    <time_frame>for 28 days following last study vaccine dose administration</time_frame>
    <description>Spontaneously reported adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of participants reporting serious adverse events</measure>
    <time_frame>for 12 months following last study vaccine dose administration</time_frame>
    <description>Unsolicited adverse events that meet the definition of serious</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of participants reporting medically attended adverse events</measure>
    <time_frame>for 12 months following last study vaccine dose administration</time_frame>
    <description>Unsolicited adverse events that lead to healthcare provider visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of participants reporting new onset of chronic disease</measure>
    <time_frame>for 12 months following last study vaccine dose administration</time_frame>
    <description>Unsolicited adverse events associated with new diagnosis of chronic disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of participants with abnormal safety laboratory test values</measure>
    <time_frame>for 28 days following last study vaccine dose administration</time_frame>
    <description>Chemistry and hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of participants with abnormal vital sign assessments</measure>
    <time_frame>for 12 months following last study vaccine dose administration</time_frame>
    <description>Blood pressure, heart rate, respiratory rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs</measure>
    <time_frame>for 12 months following last study vaccine dose administration for participants dosed in ARCT-021-02 study and for 15 months following last study vaccine dose administration for participants dose in the ARCT-021-01 study</time_frame>
    <description>Neutralizing antibody response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 binding antibody levels, expressed as GMCs</measure>
    <time_frame>for 12 months following last study vaccine dose administration for participants dosed in ARCT-021-02 study and for 15 months following last study vaccine dose administration for participants dose in the ARCT-021-01 study</time_frame>
    <description>Binding antibody response</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>ARCT-021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of ARCT-021 on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long-term follow up from ARCT-021-01</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will not receive intervention but will be followed for safety.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ARCT-021</intervention_name>
    <description>ARCT-021 single dose</description>
    <arm_group_label>ARCT-021</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Individuals who:&#xD;
&#xD;
          1. are able to give consent&#xD;
&#xD;
          2. must have completed Study ARCT-021-01&#xD;
&#xD;
          3. agree to comply with all study visits and procedures&#xD;
&#xD;
             Only for subjects that will receive ARCT-021 in this study:&#xD;
&#xD;
          4. are healthy and medically stable&#xD;
&#xD;
          5. are not planning to donate blood or plasma until 28 days after the last dose of&#xD;
             ARCT-021.&#xD;
&#xD;
          6. are willing to refrain from strenuous exercise/activity and alcohol for at least 72&#xD;
             hours prior to study visits and until 28 days after the last dose of ARCT-021.&#xD;
&#xD;
          7. are willing to adhere to contraception requirements if sexually active and/or are of&#xD;
             child-bearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Individuals who:&#xD;
&#xD;
          1. are unable to comply with the study visits or procedures in Study ARCT-021-01&#xD;
&#xD;
          2. received placebo in the Parent Study and who are not willing to receive ARCT-021 in&#xD;
             this study.&#xD;
&#xD;
             Only for subjects that will receive ARCT-021 in this study:&#xD;
&#xD;
          3. have or will receive any of the SARS CoV-2 or another experimental coronavirus during&#xD;
             this study.&#xD;
&#xD;
          4. have a diagnosis of new clinically significant abnormalities including but not limited&#xD;
             to&#xD;
&#xD;
               -  Respiratory disease requiring daily medications or oxygen currently or any&#xD;
                  treatment of respiratory disease exacerbations&#xD;
&#xD;
               -  Significant heart conditions&#xD;
&#xD;
               -  Significant neurological conditions&#xD;
&#xD;
               -  Significant blood disorders&#xD;
&#xD;
               -  Newly diagnosed autoimmune disease&#xD;
&#xD;
               -  Major surgery&#xD;
&#xD;
          5. have abnormal screening laboratory results&#xD;
&#xD;
          6. have uncontrolled diabetes&#xD;
&#xD;
          7. use of any prescription or over-the-counter medications within 7 days prior to&#xD;
             vaccination&#xD;
&#xD;
          8. have received immunoglobulins and/or any blood or blood products&#xD;
&#xD;
          9. have a bleeding disorder&#xD;
&#xD;
         10. have uncontrolled blood pressure&#xD;
&#xD;
         11. have been treated with another investigational drug, biological agent, or device since&#xD;
             completion of the Parent Study&#xD;
&#xD;
         12. have received or plan to receive:&#xD;
&#xD;
               -  A licensed, live vaccine within 4 weeks before or after study vaccination, or&#xD;
&#xD;
               -  A licensed, inactivated vaccine within 2 weeks before or after study vaccination&#xD;
&#xD;
         13. have traveled outside of Singapore within 30 days before the vaccination or plans to&#xD;
             travel outside of Singapore within 60 days after vaccination.&#xD;
&#xD;
         14. other restrictions may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arcturus Therapeutics</last_name>
    <phone>858-900-2660</phone>
    <email>clinicaltrials@arcturusrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SingHealth Investigational Medicine Unit (IMU), Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michellore Aguilar</last_name>
      <phone>+65 6322 7544</phone>
      <email>imu@singhealth.com.sg</email>
    </contact>
    <investigator>
      <last_name>Jenny Low Guek Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 24, 2021</study_first_submitted>
  <study_first_submitted_qc>January 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>January 24, 2021</last_update_submitted>
  <last_update_submitted_qc>January 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

